Donepezil also was found to change the expression of genes in the treated group. These included genes involved in mitochondrial regulation and function, fatty acid metabolism and muscle protein ...

Dr. Paul Aisen answers the question: 'Using Aricept for Alzheimer's Disease?' May 4, 2009 -- Question: What is Aricept (donepezil), how does it work and when is it used? Answer: Aricept is the ...

In a 24-week double-blind, placebo-controlled, parallel-group trial, the Donepezil 307 Study Group randomized 603 patients with probable or possible vascular dementia according to NINDS-AIREN ...

Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment without a genetic test. Researchers discovered ...

Pierre Tariot of the University of Rochester Medical Center, New York, with other clinicians of the Memantine Study Group, presented the first report to date of a prospective, double-blind, ...

Results The response ratio (MMSE 3+) of donepezil was 37.5% in N2. The combination of donepezil with the psychosocial intervention improved the Vitality Index total score, and Communication ...

In a Phase 4 trial, 14 months of donepezil treatment failed to slow cognitive decline in depressed patients with MCI. “This is a huge population,” said Murali Doraiswamy, Duke University School of ...

The study, "Combine use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer's disease patients", was released this month in Communications Medicine, ...

BRIDGEWATER, N.J., January 23, 2025--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved memantine ...

If you have Alzheimer's disease, and your doctor thinks that donepezil, galantamine, rivastigmine or memantine is the right treatment, you should be able to have the treatment on the NHS. Donezepil, ...

According to IQVIA ®, U.S. annual sales for memantine/donepezil tablets, everolimus tablets and rifaximin tablets for the 12 months ended November 2024 were approximately $88 million, $114 ...